Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-115-8231869
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£284,000.00
Profitability
Miscellaneous
Employees52
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable
Oncimmune (LON:ONC) Frequently Asked Questions
What is Oncimmune's stock symbol?
Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."
How were Oncimmune's earnings last quarter?
Oncimmune Holdings PLC (LON:ONC) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The firm earned $0.08 million during the quarter. View Oncimmune's Earnings History.
When is Oncimmune's next earnings date?
Has Oncimmune been receiving favorable news coverage?
News headlines about ONC stock have been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncimmune earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Oncimmune.
Who are some of Oncimmune's key competitors?
Some companies that are related to Oncimmune include Senseonics (SENS), Senseonics (SENS), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), Yourgene Health (YGEN), MaxCyte (MXCT), Sernova (SVA), BARD1 Life Sciences (BD1), Lexagene (LXG), Oncosil Medical (OSL), GeneNews (GEN), Deepmatter Group (DMTR), SQI Diagnostics (SQD) and Imagion Biosys (IBX).
Who are Oncimmune's key executives?
Oncimmune's management team includes the folowing people:
- Dr. Adam Mark Hill Ph.D., CEO & Director (Age 39)
- Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 52)
- Mr. Matthew Hall, Group Chief Financial Officer
- Dr. Laura J. Peek, Principal Scientist & Assistant Lab Director
- Mr. Andrew Stewart, Gen. Counsel & Company Sec.
How do I buy shares of Oncimmune?
Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oncimmune's stock price today?
One share of ONC stock can currently be purchased for approximately GBX 90.
How big of a company is Oncimmune?
What is Oncimmune's official website?
How can I contact Oncimmune?
Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.
MarketBeat Community Rating for Oncimmune (LON ONC)
MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
